Lexicon (LXRX) Pharmaceuticals announced a new analysis of its Phase 3 SCORED clinical trial demonstrating the protective effects of sotagliflozin in patients with diabetic kidney disease, DKD. Data will be presented at Kidney Week 2024, the annual meeting of the American Society of Nephrology in San Diego, California. Details for the presentation are as follows: Within the entire cohort of 10,574 participants, a placebo-adjusted acute decline in eGFR of -2.59 ml/min/1.73m2/year was observed. The total placebo-adjusted slope was -0.08 ml/min/1.73m2/year. Compared to placebo, sotagliflozin had a greater benefit on chronic slope with increasing baseline albuminuria.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXRX:
- Lexicon’s LX9211 progressing ahead of schedule, says H.C. Wainwright
- Lexicon completes screening in Phase 2B progress study of LX9211
- Lexicon signs licensing agreement with Viatris for sotagliflozin
- Lexicon receives $25M upfront from Viatris for exclusive sotagliflozin license
- Lexicon to present Phase 3 trial design for sotagliflozin in HCM